Table III.
Univariate and multivariate model of HHV-8 shedding rate for persons completing both study arms.
Univariate | Multivariate | |||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
IRR | 95% CI | P-value | IRR | 95% CI | P-value | |||
| ||||||||
Age | 0.95 | 0.88 | 1.03 | 0.22 | ||||
| ||||||||
Ethnicity | ||||||||
Black* | 1.23 | 0.19 | 8.21 | 0.83 | ||||
Peruvian* | 2.35 | 0.45 | 12.39 | 0.31 | ||||
Other* | 2.39 | 0.15 | 38.90 | 0.54 | ||||
| ||||||||
Days when genital HSV detected compared to days when no genital HSV detected | 0.97 | 0.79 | 1.19 | 0.75 | ||||
| ||||||||
CD4 count, for every 100 increase | 0.92 | 0.69 | 1.22 | 0.54 | ||||
| ||||||||
HIV log10 copies/ml, for each log increase | 1.78 | 1.17 | 2.71 | 0.01 | 1.10 | 0.59 | 2.04 | 0.77 |
| ||||||||
HAART vs. no HAART | 0.11 | 0.03 | 0.42 | 0.001 | 0.13 | 0.02 | 0.99 | 0.05 |
| ||||||||
Valaciclovir vs. placebo | 0.82 | 0.71 | 0.95 | 0.01 | 0.82 | 0.71 | 0.96 | 0.01 |
| ||||||||
Famciclovir vs placebo | 0.70 | 0.58 | 0.84 | <0.001 | 0.70 | 0.58 | 0.84 | <0.001 |
Compared to white race